{"id":49049,"date":"2025-11-26T16:26:58","date_gmt":"2025-11-26T08:26:58","guid":{"rendered":"https:\/\/flcube.com\/?p=49049"},"modified":"2025-11-26T16:26:58","modified_gmt":"2025-11-26T08:26:58","slug":"humanwells-lisdexamfetamine-nda-accepted-by-nmpa-for-adhd-first-generic-potential","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49049","title":{"rendered":"Humanwell&#8217;s Lisdexamfetamine NDA Accepted by NMPA for ADHD, First Generic Potential"},"content":{"rendered":"\n<p><strong>Humanwell Healthcare (Group) Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600079:SHA\">SHA: 600079<\/a>) announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has accepted its marketing application for <strong>lisdexamfetamine<\/strong>, a <strong>Class\u202f3 generic<\/strong> for treating <strong>ADHD<\/strong> in adults and pediatric patients aged <strong>6\u202fyears and older<\/strong>, positioning Humanwell as the <strong>potential first\u2011to\u2011market<\/strong> generic in China.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Lisdexamfetamine (Class\u202f3 generic)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Humanwell Healthcare (Group) Co., Ltd. (600079.SH)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Application Type<\/strong><\/td><td>Marketing authorization (generic)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>ADHD in adults and pediatric patients aged \u22656\u202fyears<\/td><\/tr><tr><td><strong>Market Status<\/strong><\/td><td><strong>No generic or imported lisdexamfetamine<\/strong> approved in China currently<\/td><\/tr><tr><td><strong>Next Step<\/strong><\/td><td>Technical review; approval expected Q3\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Originator:<\/strong> <strong>Takeda<\/strong> (first approved in U.S. 2007; brand: Vyvanse)<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Prodrug of dextroamphetamine; <strong>CNS stimulant<\/strong> for ADHD<\/li>\n\n\n\n<li><strong>Additional Indication:<\/strong> Also approved for <strong>moderate\u2011to\u2011severe Binge Eating Disorder (BED)<\/strong> in adults in the U.S. (not included in China application yet)<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Class\u202f3 generic pathway offers <strong>12\u2011month regulatory review<\/strong> vs. 24\u2011month for Class\u202f4\/5<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>China ADHD Diagnosed Patients<\/strong><\/td><td>~10\u202fmillion children + 5\u202fmillion adults (2024)<\/td><\/tr><tr><td><strong>Treatment Rate<\/strong><\/td><td>&lt;20% of pediatric, &lt;5% of adult patients currently treated<\/td><\/tr><tr><td><strong>CNS Stimulant Market<\/strong><\/td><td>\u00a58.5\u202fbillion (US$1.2\u202fbillion) in 2024; growing at 15% CAGR<\/td><\/tr><tr><td><strong>Lisdexamfetamine Potential<\/strong><\/td><td><strong>\u00a51.5\u20112.0\u202fbillion<\/strong> peak sales by 2030 (assuming 10% share of stimulant market)<\/td><\/tr><tr><td><strong>Pricing<\/strong><\/td><td>Expected 30\u201140% discount to originator pricing when launched in China<\/td><\/tr><tr><td><strong>Competition<\/strong><\/td><td><strong>First generic applicant<\/strong>; potential <strong>12\u2011month exclusivity<\/strong> if approved before other generics<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Advantage:<\/strong> NMPA\u2019s acceptance signals <strong>bioequivalence<\/strong> data adequacy; no clinical efficacy trials required for Class\u202f3<\/li>\n\n\n\n<li><strong>Commercial Strategy:<\/strong> Humanwell can leverage existing <strong>CNS distribution network<\/strong> and hospital relationships from its other psychiatry products<\/li>\n\n\n\n<li><strong>Patient Access:<\/strong> Generic entry expected to improve <strong>affordability<\/strong> and drive <strong>market penetration<\/strong> in tier\u20112\/3 cities<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding lisdexamfetamine\u2019s approval timeline, market potential, and competitive position. Actual results may differ materially due to risks including NMPA review outcomes, competitive dynamics, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/600079_20251122_920A.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600079_20251122_920A.\"><\/object><a id=\"wp-block-file--media-08102214-1333-4454-98ef-44cad5ee0ef1\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/600079_20251122_920A.pdf\">600079_20251122_920A<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/600079_20251122_920A.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-08102214-1333-4454-98ef-44cad5ee0ef1\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that the National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49052,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[42,266,38,1098],"class_list":["post-49049","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-first-mover-generic","tag-humanwell-healthcare","tag-market-approval-filings","tag-sha-600079"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Humanwell&#039;s Lisdexamfetamine NDA Accepted by NMPA for ADHD, First Generic Potential - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that the National Medical Products Administration (NMPA) has accepted its marketing application for lisdexamfetamine, a Class\u202f3 generic for treating ADHD in adults and pediatric patients aged 6\u202fyears and older, positioning Humanwell as the potential first\u2011to\u2011market generic in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49049\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Humanwell&#039;s Lisdexamfetamine NDA Accepted by NMPA for ADHD, First Generic Potential\" \/>\n<meta property=\"og:description\" content=\"Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that the National Medical Products Administration (NMPA) has accepted its marketing application for lisdexamfetamine, a Class\u202f3 generic for treating ADHD in adults and pediatric patients aged 6\u202fyears and older, positioning Humanwell as the potential first\u2011to\u2011market generic in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49049\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-26T08:26:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2609.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49049#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49049\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Humanwell&#8217;s Lisdexamfetamine NDA Accepted by NMPA for ADHD, First Generic Potential\",\"datePublished\":\"2025-11-26T08:26:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49049\"},\"wordCount\":323,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49049#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2609.webp\",\"keywords\":[\"First-mover generic\",\"Humanwell Healthcare\",\"Market approval filings\",\"SHA: 600079\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49049#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49049\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49049\",\"name\":\"Humanwell's Lisdexamfetamine NDA Accepted by NMPA for ADHD, First Generic Potential - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49049#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49049#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2609.webp\",\"datePublished\":\"2025-11-26T08:26:58+00:00\",\"description\":\"Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that the National Medical Products Administration (NMPA) has accepted its marketing application for lisdexamfetamine, a Class\u202f3 generic for treating ADHD in adults and pediatric patients aged 6\u202fyears and older, positioning Humanwell as the potential first\u2011to\u2011market generic in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49049#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49049\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49049#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2609.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2609.webp\",\"width\":1080,\"height\":608,\"caption\":\"Humanwell's Lisdexamfetamine NDA Accepted by NMPA for ADHD, First Generic Potential\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49049#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Humanwell&#8217;s Lisdexamfetamine NDA Accepted by NMPA for ADHD, First Generic Potential\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Humanwell's Lisdexamfetamine NDA Accepted by NMPA for ADHD, First Generic Potential - Insight, China&#039;s Pharmaceutical Industry","description":"Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that the National Medical Products Administration (NMPA) has accepted its marketing application for lisdexamfetamine, a Class\u202f3 generic for treating ADHD in adults and pediatric patients aged 6\u202fyears and older, positioning Humanwell as the potential first\u2011to\u2011market generic in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49049","og_locale":"en_US","og_type":"article","og_title":"Humanwell's Lisdexamfetamine NDA Accepted by NMPA for ADHD, First Generic Potential","og_description":"Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that the National Medical Products Administration (NMPA) has accepted its marketing application for lisdexamfetamine, a Class\u202f3 generic for treating ADHD in adults and pediatric patients aged 6\u202fyears and older, positioning Humanwell as the potential first\u2011to\u2011market generic in China.","og_url":"https:\/\/flcube.com\/?p=49049","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-26T08:26:58+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2609.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49049#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49049"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Humanwell&#8217;s Lisdexamfetamine NDA Accepted by NMPA for ADHD, First Generic Potential","datePublished":"2025-11-26T08:26:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49049"},"wordCount":323,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49049#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2609.webp","keywords":["First-mover generic","Humanwell Healthcare","Market approval filings","SHA: 600079"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49049#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49049","url":"https:\/\/flcube.com\/?p=49049","name":"Humanwell's Lisdexamfetamine NDA Accepted by NMPA for ADHD, First Generic Potential - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49049#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49049#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2609.webp","datePublished":"2025-11-26T08:26:58+00:00","description":"Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that the National Medical Products Administration (NMPA) has accepted its marketing application for lisdexamfetamine, a Class\u202f3 generic for treating ADHD in adults and pediatric patients aged 6\u202fyears and older, positioning Humanwell as the potential first\u2011to\u2011market generic in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49049#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49049"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49049#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2609.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2609.webp","width":1080,"height":608,"caption":"Humanwell's Lisdexamfetamine NDA Accepted by NMPA for ADHD, First Generic Potential"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49049#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Humanwell&#8217;s Lisdexamfetamine NDA Accepted by NMPA for ADHD, First Generic Potential"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2609.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49049","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49049"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49049\/revisions"}],"predecessor-version":[{"id":49053,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49049\/revisions\/49053"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49052"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49049"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49049"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49049"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}